Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030353191> ?p ?o ?g. }
- W3030353191 abstract "Background: Organ-specific response patterns reported in previous studies indicate different response towards immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) patients with different metastatic sites. This study aims to compare the efficacy of ICIs with conventional therapy in NSCLC patients with bone, brain or liver metastases. Materials and Methods: MEDLINE, Embase and CENTRAL were searched for studies comparing ICIs with conventional therapy in NSCLC patients with bone, brain or liver metastases. The pooled hazard ratio (HR) of overall survival (OS) and progression-free survival (PFS) among included studies was analyzed using the random effects model. Results: Eight studies consisting of 988 NSCLC patients were included, 259 with brain metastases and 729 with liver metastases. No available study with bone metastases information was identified. For patients with brain metastases, ICIs significantly improved their OS (HR, 0.57; 95%CI, 0.37-0.86; P = 0.007). For patients with liver metastases, both OS (HR, 0.72; 95%CI, 0.57-0.91; P = 0.006) and PFS (HR, 0.72; 95%CI, 0.49-0.87; P = 0.004) improvements were observed in the ICI treatment arm. Subgroup analysis was conducted based on target of ICIs and treatment regimen. PD-1 inhibitors could benefit patients on OS and PFS regardless of metastatic sites, while PD-L1 inhibitors could not. Patients with brain metastases could only gain OS improvement from ICIs combined with chemotherapy, but for patients with liver metastases, the benefit was detected using ICIs single agent or ICIs combined with chemotherapy plus anti-VEGF therapy. Conclusion: ICIs could significantly improve OS in NSCLC patients with brain or liver metastases compared with conventional therapy. Although brain and liver metastases are generally considered as poor prognostic factors for immunotherapy, this study still indicates ICIs are effective therapeutic options for NSCLC patients with these metastatic sites." @default.
- W3030353191 created "2020-06-05" @default.
- W3030353191 creator A5052713745 @default.
- W3030353191 creator A5060021711 @default.
- W3030353191 creator A5078614195 @default.
- W3030353191 creator A5079451346 @default.
- W3030353191 creator A5082110547 @default.
- W3030353191 date "2020-07-09" @default.
- W3030353191 modified "2023-10-17" @default.
- W3030353191 title "Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis" @default.
- W3030353191 cites W1760562407 @default.
- W3030353191 cites W1913780655 @default.
- W3030353191 cites W1974378453 @default.
- W3030353191 cites W2012295597 @default.
- W3030353191 cites W2047259303 @default.
- W3030353191 cites W2054841768 @default.
- W3030353191 cites W2069220094 @default.
- W3030353191 cites W2087990556 @default.
- W3030353191 cites W2098923148 @default.
- W3030353191 cites W2101653483 @default.
- W3030353191 cites W2156098321 @default.
- W3030353191 cites W2160834915 @default.
- W3030353191 cites W2205987892 @default.
- W3030353191 cites W2254024193 @default.
- W3030353191 cites W2301488980 @default.
- W3030353191 cites W2416906314 @default.
- W3030353191 cites W2468996569 @default.
- W3030353191 cites W2493219106 @default.
- W3030353191 cites W2508069933 @default.
- W3030353191 cites W2527905628 @default.
- W3030353191 cites W2560367415 @default.
- W3030353191 cites W2566197782 @default.
- W3030353191 cites W2588681363 @default.
- W3030353191 cites W2595863515 @default.
- W3030353191 cites W2607272476 @default.
- W3030353191 cites W2608436322 @default.
- W3030353191 cites W2626568439 @default.
- W3030353191 cites W2626773261 @default.
- W3030353191 cites W2745683917 @default.
- W3030353191 cites W2768743357 @default.
- W3030353191 cites W2783469772 @default.
- W3030353191 cites W2790743957 @default.
- W3030353191 cites W2796582438 @default.
- W3030353191 cites W2802142055 @default.
- W3030353191 cites W2806145489 @default.
- W3030353191 cites W2885907209 @default.
- W3030353191 cites W2889444510 @default.
- W3030353191 cites W2889646458 @default.
- W3030353191 cites W2890861541 @default.
- W3030353191 cites W2892640821 @default.
- W3030353191 cites W2898352237 @default.
- W3030353191 cites W2905870269 @default.
- W3030353191 cites W2906932524 @default.
- W3030353191 cites W2908622615 @default.
- W3030353191 cites W2920855799 @default.
- W3030353191 cites W2924289105 @default.
- W3030353191 cites W2925446385 @default.
- W3030353191 cites W2940771671 @default.
- W3030353191 cites W2946386783 @default.
- W3030353191 cites W2973398949 @default.
- W3030353191 cites W2980525484 @default.
- W3030353191 cites W2981790403 @default.
- W3030353191 cites W2988979571 @default.
- W3030353191 cites W2990769829 @default.
- W3030353191 cites W2991483702 @default.
- W3030353191 cites W2996681083 @default.
- W3030353191 cites W2998269674 @default.
- W3030353191 cites W3000339487 @default.
- W3030353191 cites W3009099064 @default.
- W3030353191 cites W3014106859 @default.
- W3030353191 cites W3014209163 @default.
- W3030353191 cites W3125307637 @default.
- W3030353191 cites W4234236664 @default.
- W3030353191 doi "https://doi.org/10.3389/fonc.2020.01098" @default.
- W3030353191 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7363957" @default.
- W3030353191 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32733805" @default.
- W3030353191 hasPublicationYear "2020" @default.
- W3030353191 type Work @default.
- W3030353191 sameAs 3030353191 @default.
- W3030353191 citedByCount "27" @default.
- W3030353191 countsByYear W30303531912021 @default.
- W3030353191 countsByYear W30303531912022 @default.
- W3030353191 countsByYear W30303531912023 @default.
- W3030353191 crossrefType "journal-article" @default.
- W3030353191 hasAuthorship W3030353191A5052713745 @default.
- W3030353191 hasAuthorship W3030353191A5060021711 @default.
- W3030353191 hasAuthorship W3030353191A5078614195 @default.
- W3030353191 hasAuthorship W3030353191A5079451346 @default.
- W3030353191 hasAuthorship W3030353191A5082110547 @default.
- W3030353191 hasBestOaLocation W30303531911 @default.
- W3030353191 hasConcept C126322002 @default.
- W3030353191 hasConcept C143998085 @default.
- W3030353191 hasConcept C207103383 @default.
- W3030353191 hasConcept C2776256026 @default.
- W3030353191 hasConcept C2776694085 @default.
- W3030353191 hasConcept C2781413609 @default.
- W3030353191 hasConcept C44249647 @default.
- W3030353191 hasConcept C71924100 @default.
- W3030353191 hasConcept C95190672 @default.
- W3030353191 hasConceptScore W3030353191C126322002 @default.